Royalty Pharma plc is a biotechnology business based in the US. Royalty Pharma plc shares (RPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.01 – an increase of 0.62% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $26.01 |
|---|---|
| 52-week range | $24.80 - $30.92 |
| 50-day moving average | $27.60 |
| 200-day moving average | $28.11 |
| Wall St. target price | $41.43 |
| PE ratio | 10.1912 |
| Dividend yield | $0.83 (3.25%) |
| Earnings per share (TTM) | $2.51 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $25.8 from 2024-11-18
| 1 week (2024-11-14) | 1.69% |
|---|---|
| 1 month (2024-10-18) | -7.79% |
| 3 months (2024-08-20) | -5.36% |
| 6 months (2024-05-20) | -6.11% |
| 1 year (2023-11-20) | -4.20% |
|---|---|
| 2 years (2022-11-18) | -36.34% |
| 3 years (2021-11-19) | 38.5841 |
| 5 years (2019-11-17) | N/A |
Valuing Royalty Pharma plc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Royalty Pharma plc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Royalty Pharma plc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Royalty Pharma plc shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Royalty Pharma plc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Royalty Pharma plc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.3929. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Royalty Pharma plc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Royalty Pharma plc's PEG ratio in relation to those of similar companies.
Royalty Pharma plc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 billion.
The EBITDA is a measure of a Royalty Pharma plc's overall financial performance and is widely used to measure a its profitability.
To put Royalty Pharma plc's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $2.3 billion |
|---|---|
| Operating margin TTM | 130.17% |
| Gross profit TTM | $1.3 billion |
| Return on assets TTM | 5.69% |
| Return on equity TTM | 17.28% |
| Profit margin | 50.53% |
| Book value | $15.40 |
| Market Capitalization | $15.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 20.49% of net profits
Recently Royalty Pharma plc has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Royalty Pharma plc shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Royalty Pharma plc's case, that would currently equate to about $0.83 per share.
While Royalty Pharma plc's payout ratio might seem low, this can signify that Royalty Pharma plc is investing more in its future growth.
Royalty Pharma plc's most recent dividend payout was on 9 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 November 2024 (the "ex-dividend date").
Royalty Pharma plc's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Over the last 12 months, Royalty Pharma plc's shares have ranged in value from as little as $24.8016 up to $30.9227. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Royalty Pharma plc's is 0.466. This would suggest that Royalty Pharma plc's shares are less volatile than average (for this exchange).
To put Royalty Pharma plc's beta into context you can compare it against those of similar companies.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.